Cargando…

Stratified approaches for using biomarkers in phenotyping for the management of severe asthma in India

Various respiratory societies including the Global Initiative for Asthma (GINA), European Respiratory Society (ERS) and American Thoracic Society (ATS) define severe asthma as asthma that requires or remains uncontrolled despite treatment with systemic corticosteroids or high-dose inhaled corticoste...

Descripción completa

Detalles Bibliográficos
Autores principales: Talwar, Deepak, Singh, Sarvinder, Marwah, Vikas, Asawale, Ketan, Bhushan, Bharat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926217/
https://www.ncbi.nlm.nih.gov/pubmed/34975055
http://dx.doi.org/10.4103/lungindia.lungindia_129_21
_version_ 1784670191675768832
author Talwar, Deepak
Singh, Sarvinder
Marwah, Vikas
Asawale, Ketan
Bhushan, Bharat
author_facet Talwar, Deepak
Singh, Sarvinder
Marwah, Vikas
Asawale, Ketan
Bhushan, Bharat
author_sort Talwar, Deepak
collection PubMed
description Various respiratory societies including the Global Initiative for Asthma (GINA), European Respiratory Society (ERS) and American Thoracic Society (ATS) define severe asthma as asthma that requires or remains uncontrolled despite treatment with systemic corticosteroids or high-dose inhaled corticosteroids plus another controller such as long acting beta agonist. The management of asthma as an entity is not straightforward due to inter-individual variability in assessment parameters. With the advent of science, targeted therapies are on the emergence for management of severe asthma. A biomarker can be used as a surrogate to phenotype a patient as well as to measure the response to therapy with any drug. Biomarkers have been critical for studies of disease pathogenesis and the development of new therapies in severe asthma. From a resource constraint perspective like countries in India, it is imperative to use biomarkers that are easily available are affordable cost. Choosing an ideal biomarkers is also important from a perspective of choosing a particular therapy. The cost associated with the biologicals is high and it is imperative to gauge the treatment effectiveness with the therapy at the earliest considering the out of pocket spends of the patients.
format Online
Article
Text
id pubmed-8926217
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-89262172022-03-17 Stratified approaches for using biomarkers in phenotyping for the management of severe asthma in India Talwar, Deepak Singh, Sarvinder Marwah, Vikas Asawale, Ketan Bhushan, Bharat Lung India Review Article Various respiratory societies including the Global Initiative for Asthma (GINA), European Respiratory Society (ERS) and American Thoracic Society (ATS) define severe asthma as asthma that requires or remains uncontrolled despite treatment with systemic corticosteroids or high-dose inhaled corticosteroids plus another controller such as long acting beta agonist. The management of asthma as an entity is not straightforward due to inter-individual variability in assessment parameters. With the advent of science, targeted therapies are on the emergence for management of severe asthma. A biomarker can be used as a surrogate to phenotype a patient as well as to measure the response to therapy with any drug. Biomarkers have been critical for studies of disease pathogenesis and the development of new therapies in severe asthma. From a resource constraint perspective like countries in India, it is imperative to use biomarkers that are easily available are affordable cost. Choosing an ideal biomarkers is also important from a perspective of choosing a particular therapy. The cost associated with the biologicals is high and it is imperative to gauge the treatment effectiveness with the therapy at the earliest considering the out of pocket spends of the patients. Wolters Kluwer - Medknow 2022 2021-12-28 /pmc/articles/PMC8926217/ /pubmed/34975055 http://dx.doi.org/10.4103/lungindia.lungindia_129_21 Text en Copyright: © 2021 Indian Chest Society https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Talwar, Deepak
Singh, Sarvinder
Marwah, Vikas
Asawale, Ketan
Bhushan, Bharat
Stratified approaches for using biomarkers in phenotyping for the management of severe asthma in India
title Stratified approaches for using biomarkers in phenotyping for the management of severe asthma in India
title_full Stratified approaches for using biomarkers in phenotyping for the management of severe asthma in India
title_fullStr Stratified approaches for using biomarkers in phenotyping for the management of severe asthma in India
title_full_unstemmed Stratified approaches for using biomarkers in phenotyping for the management of severe asthma in India
title_short Stratified approaches for using biomarkers in phenotyping for the management of severe asthma in India
title_sort stratified approaches for using biomarkers in phenotyping for the management of severe asthma in india
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926217/
https://www.ncbi.nlm.nih.gov/pubmed/34975055
http://dx.doi.org/10.4103/lungindia.lungindia_129_21
work_keys_str_mv AT talwardeepak stratifiedapproachesforusingbiomarkersinphenotypingforthemanagementofsevereasthmainindia
AT singhsarvinder stratifiedapproachesforusingbiomarkersinphenotypingforthemanagementofsevereasthmainindia
AT marwahvikas stratifiedapproachesforusingbiomarkersinphenotypingforthemanagementofsevereasthmainindia
AT asawaleketan stratifiedapproachesforusingbiomarkersinphenotypingforthemanagementofsevereasthmainindia
AT bhushanbharat stratifiedapproachesforusingbiomarkersinphenotypingforthemanagementofsevereasthmainindia